• Cumberland Pharmaceuticals held a shareholder meeting on July 1, 2026.
• Shareholders adopted a resolution authorizing the strategic transaction with Apotex to integrate their branded U.S. businesses.
• The transaction was subsequently executed, with Apotex acquiring Cumberland’s branded pharmaceuticals for USD 100 million paid at closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cumberland Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607010900PR_NEWS_USPR_____CL95903) on July 01, 2026, and is solely responsible for the information contained therein.